Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633800 | 0.88 | NPC1 (0.54) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL30306655 | 0.88 | NPC1 (0.54) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24011431 | 0.83 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24011268 | 0.83 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24011088 | 0.81 | SMN1; SMN2 (0.74) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24011294 | 0.81 | SMN1; SMN2 (0.58) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24448792 | 0.79 | SMN1; SMN2 (0.71) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL4980231 | 0.79 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL28874179 | 0.78 | SMN1; SMN2 (0.78) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL24011182 | 0.78 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | RAB9A 814/4885NPC1 128/4885SMN1; SMN2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.